CompletedNCT05163496
Frontline Clinician Psilocybin Study
Medication studyAges 18+United StatesPTSD
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- SeattleSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: March 3, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 30
- Sponsor
- University of Washington
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT05163496
- Official title
Show the full official title
A Randomized, Placebo-controlled Trial of Psychedelic-assisted Psychotherapy With Single Dose Psilocybin for Frontline Clinicians Experiencing COVID-related Symptoms of Depression and Burnout
Recruitment & locations
CompletedSeattle
Questions about this study
Who is behind this study?
The study sponsor is University of Washington, a university.
Did this study involve medication?
Yes. The study involved medication, including Psilocybin (Usona Institute) and Active placebo.
Who was this study for?
Listed age limits: from 18 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me